|
Canada-0-MEDITATION företaget Kataloger
|
Företag Nyheter:
- Perioperative pembrolizumab and lenvatinib for resectable . . .
Background: The high recurrence rate after resection hinders the survival of patients with resectable hepatocellular carcinoma (HCC) Perioperative treatment has the potential to reduce the burdenof micrometastasis and improve outcomesin many types ofcancers This study aims to evaluate the efficacy and safety of pembrolizumab plus lenvatinib as perioperative treatment in patients with
- Perioperative pembrolizumab and lenvatinib for. . . : Journal of Clinical . . .
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC)
- Study Details | NCT05389527 | Pembrolizumab and Lenvatinib for . . .
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab as a neoadjuvant therapy in subjects with resectable hepatocellular carcinoma (HCC)
- 挽救曾被认定无法手术的肝癌患者的创新手术实验成功
在肝癌治疗领域，一项创新手术的成功为那些曾被认为无法手术的患者带来了新的希望。2025年2月，由复旦大学附属中山医院孙惠川教授牵头的多中心单臂Ⅱ期NeoLEAP-HCC研究取得重大突破。该研究通过联合仑伐替尼和帕博利珠单抗（“可乐组合”）作为围手术期治疗方案，成功将部分原本不可切除的
- Lancet Oncol | 仑伐替尼加帕博利珠单抗与仑伐替尼加安慰剂 . . .
该研究旨在评估仑伐替尼和帕博利珠单抗联合一线治疗HCC的疗效和安全性，联合治疗未达到主要终点，推荐继续开展仑伐替尼+帕博利珠单抗联合其他局部治疗，可以作为一线治疗的备选方案。
- ASCO 2024: Perioperative pembrolizumab and lenvatinib for resectable . . .
Figures for ASCO 2024 European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1 2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)
- The Combination of Pembrolizumab and Lenvatinib as Neoadjuvant . . .
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab as a
- 201P Perioperative pembrolizumab and lenvatinib for resectable . . .
The single-arm, multicenter, phase II NeoLEAP-HCC study (NCT05389527) was conducted to evaluate the efficacy and safety of pembrolizumab plus lenvatinib as perioperative treatment in patients (pts) with resectable hepatocellular carcinoma (HCC) We have reported that the major pathological response (MPR) rate was 37 8% Here, we report the updated perioperative efficacy and safety results
- 派姆单抗+乐伐替尼 在 癌，肝细胞癌-临床试验注册中心 . . .
肝细胞癌（HCC）根治性手术后的复发率高，生存获益有限。 新辅助治疗，通过在根治性手术前靶向播散的肿瘤细胞，可以降低肿瘤复发的发生率。 在 KEYNOTE-524 研究中，lenvatinib 加 pembrolizumab 组合显示出有前途的疗效和可控的毒性。 本研究将评估乐伐替尼联合帕博利珠单抗作为可切除 HCC 受试者新
- LEAP-012: Pembrolizumab Plus Lenvatinib Added to TACE Improved . . .
According to results of the first interim analysis of the phase III LEAP-012 trial, the anti–PD-1 therapy pembrolizumab plus the tyrosine kinase inhibitor lenvatinib, in combination with transarterial chemoembolization (TACE), significantly improved progression-free survival compared with TACE alone for the treatment of patients with unresectable, nonmetastatic hepatocellular carcinoma (HCC
|
|